

This Page Is Inserted by IFW Operations
and is not a part of the Official Record

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

IMAGES ARE BEST AVAILABLE COPY.

**As rescanning documents *will not* correct images,
please do not report the images to the
Image Problem Mailbox.**



PTO/SB/21 (08-03)

Approved for use through 07/31/2006. OMB 0651-003
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

TRANSMITTAL FORM <i>(to be used for all correspondence after initial filing)</i>	Application Number	10/732,703	
	Filing Date	December 10, 2003	
	First Named Inventor	Shengwen Li	
	Art Unit	Not Yet Assigned	
	Examiner Name	Not Yet Assigned	
Total Number of Pages in This Submission	15	Attorney Docket Number	ALLE0002-100 (17665)

ENCLOSURES (check all that apply)				
<input type="checkbox"/> Fee Transmittal Form <input type="checkbox"/> Fee Attached <input type="checkbox"/> Amendment / Reply <input type="checkbox"/> After Final <input type="checkbox"/> Affidavits/declaration(s) <input type="checkbox"/> Extension of Time Request <input type="checkbox"/> Express Abandonment Request <input checked="" type="checkbox"/> Information Disclosure Statement <input type="checkbox"/> Certified Copy of Priority Document(s) <input checked="" type="checkbox"/> Response to Missing Parts/Incomplete Application <input type="checkbox"/> Response to Missing Parts under 37 CFR 1.52 or 1.53	<input type="checkbox"/> Drawing(s) <input type="checkbox"/> Licensing-related Papers <input type="checkbox"/> Petition <input type="checkbox"/> Petition to Convert to a Provisional Application <input type="checkbox"/> Power of Attorney, Revocation Change of Correspondence Address <input type="checkbox"/> Terminal Disclaimer <input type="checkbox"/> Request for Refund <input type="checkbox"/> CD, Number of CD(s) _____	<input type="checkbox"/> After Allowance Communication to Group <input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences <input type="checkbox"/> Appeal Communication to Group (Appeal Notice, Brief, Reply Brief) <input type="checkbox"/> Proprietary Information <input type="checkbox"/> Status Letter <input checked="" type="checkbox"/> Other Enclosure(s) (please identify below): References AU-EB and EE		
<table border="1"><tr><td>Remarks</td><td></td></tr></table>			Remarks	
Remarks				

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT	
Firm or Individual name	David A. Sadewasser/Reg. No. 55,587
Signature	<i>David A. Sadewasser</i>
Date	<i>April 9, 2004</i>

CERTIFICATE OF MAILING			
I hereby certify that this correspondence is being facsimile transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 145, Alexandria, VA 22313-1450 on the date shown below.			
Typed or printed name	David A. Sadewasser		
Signature	<i>April 9, 2004</i>	Date	<i>April 9, 2004</i>

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.



ALLE0002-100 (17665)

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In Re Application of: Shengwen Li, et al.

Serial No.: 10/732,703

Group Art Unit: Not Yet Assigned

Filing Date: December 10, 2003

Examiner: Not Yet Assigned

For: LIPID RAFTS AND CLOSTRIDIAL TOXINS

DATE OF DEPOSIT: April 9, 2004
I HEREBY CERTIFY THAT THIS PAPER IS BEING
DEPOSITED WITH THE UNITED STATES POSTAL
SERVICE AS FIRST CLASS MAIL, POSTAGE PREPAID ON
THE DATE INDICATED ABOVE AND IS ADDRESSED TO
THE COMMISSIONER FOR PATENTS, P.O. BOX 1450,
ALEXANDRIA, VA 22313-1450

David R. Sadewasser
TYPED NAME: David R. Sadewasser
REGISTRATION NO: 55,587

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

INFORMATION DISCLOSURE STATEMENT

Pursuant to 37 C.F.R. §§ 1.56 and in accordance with 37 C.F.R. §§ 1.97 and 1.98, information relating to the above-identified application is hereby disclosed, the Examiner in charge of the above-identified application is requested to consider and make of record the references listed on the PTO Form SB/08A and PTO Form SB/08B, formerly known as PTO Form 1449 submitted herewith.

Inclusion of the information submitted herewith is not to be construed as an admission that the information is material as that term is defined in 37 C.F.R. § 1.56(b).

In accordance with 37 C.F.R. § 1.97(g), the filing of this Information Disclosure Statement shall not be construed to mean that a search has been made.

This Information Disclosure Statement is being filed:

- ☐ within three months of the filing date of the patent application.
- ☐ within three months of the date of entry into the national stage as set forth in 37 C.F.R. § 1.491 of the international application.
- ☒ **before** the mailing date of a first Office Action on the merits.
- ☐ **after** the mailing date of a first Office Action on the merits, but before the mailing date of a Final Office Action under 37 C.F.R. § 1.116 or a Notice of Allowance under 37 C.F.R. § 1.311, and accordingly is accompanied by:
- ☐ the Statement under 37 C.F.R. § 1.97(e) (see "Statement" below);
- or**
- ☐ the Fee of \$180.00 set forth in 37 C.F.R. § 1.17(p); or
- ☐ No fee is owed by the applicant(s).
- ☐ In accordance with 37 C.F.R. § 1.129(a), this Information Disclosure Statement is being filed in connection with ☐ the first or ☐ second After Final Submission, and accordingly is accompanied by the Statement under 37 C.F.R. § 1.97(e) (see "Statement" below) and the fee of \$180.00 as set forth in 37 C.F.R. § 1.17(p), is attached.
- ☐ **after** the mailing date of a Final Office Action under 37 C.F.R. § 1.116 or a Notice of Allowance under 37 C.F.R. § 1.311, but before, or simultaneously with, the payment of the Issue Fee, and accordingly is accompanied by the Statement under 37 C.F.R. § 1.97(e), a Petition requesting consideration of the Information Disclosure Statement and the Petition Fee of \$130.00 set forth in 37 C.F.R. § 1.17(i)(1) (see "Statement," "Petition," and "Fees" below).
- ☒ Copies of references (AU-EB and EE) listed on the attached PTO Form SB/08A and PTO Form SB/08B, formerly known as PTO Form 1449 are enclosed.

EXCEPT THAT:

- ☐ In view of the voluminous nature of reference @, and the likelihood that this reference is available to the Examiner, copies are not enclosed herewith.
- ☐ In accordance with 37 C.F.R. § 1.98(d), copies of the following references listed on the attached PTO Form SB/08A and PTO Form SB/08B, formerly known as PTO Form 1449 are not enclosed herewith because they were previously cited by or submitted to the U.S. Patent and Trademark Office in patent application(s) for which a claim for priority under 35 U.S.C. § 120 have been made in the instant application.

- ☐ Copies of references listed on the attached PTO Form SB/08A and PTO Form SB/08B, formerly known as PTO Form 1449 were previously cited by or submitted to the U.S. Patent and Trademark Office in parent application Serial No. @@ filed on @@.
- ☐ If any of the foregoing publications are not available to the Examiner, Applicant will endeavor to supply copies at the Examiner's request.

Statement under 37 C.F.R. § 1.97(e)

- ☐ The undersigned attorney hereby states that each item information contained in the Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign patent application not more than three months prior to the filing of the Information Disclosure Statement.

Fees

- ☒ No Fee is owed by the applicant(s).
- ☐ The Information Disclosure Statement Fee of \$180.00 under 37 C.F.R. § 1.17(p) is enclosed herewith.
- ☐ The Petition Fee of \$130.00 under 37 C.F.R. § 1.17(i)(1) is enclosed herewith.

Method of Payment of Fees

- ☐ Attached is a check in the amount of \$_____. This form is submitted in duplicate.
- ☐ Charge Deposit Account No. 50-1275 in the amount of \$_____. This form is submitted in duplicate.
- ☒ Please charge any deficiency or credit any overpayment to Deposit Account 50-1275.

☒ No fee or Statement is required under 37 C.F.R. § 1.97(b).


Respectfully submitted,



David A. Sadewasser
Registration No. 55,587

Dated: April 9, 2004

COZEN O'CONNOR, P.C.
1900 Market Street, 5th Floor
Philadelphia, PA 19103-3508
(215) 665-2000 – Telephone
(215) 701-2013 - Facsimile



Substitute for form PTO/A9A/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet 1 of 10

Complete if Known

Application Number	10/732,703
Filing Date	December 10, 2003
First Named Inventor	Shengwen Li
Art Unit	Not Yet Assigned
Examiner Name	Not Yet Assigned
Attorney Docket Number	ALLE0002-100 (17665)

U.S. PATENT DOCUMENTS

Examiner Initials *	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number - Kind Code ² (if known)			
	AA	US-6,458,365	10/01/2002	Aoki et al	
	AB	US- 5,766,605	06/16/1998	Sanders et al	
	AC	US- 5,714,468	02/03/1998	Dao	
	AD	US- 6,464,986	10/15/2002	Aoki et al	
	AE	US- 6,113,915	09/05/2000	Aoki et al	
	AF	US- 6,306,403	10/23/2001	Donovan	
	AG	US- 6,299,893	10/09/2001	Schwartz et al	
	AH	US- 5,670,484	09/23/1997	Binder	
	AI	US- 6,423,319	07/23/2002	Brooks et al	
	AJ	US- 6,139,845	10/31/2000	Donovan	
	AK	US- 6,143,306	11/07/2000	Donovan	
	AL	US- 5,437,291	08/01/1995	Pasricha et al	
	AM	US- 6,365,164	04/02/2002	Schmidt	
	AN	US- 6,063,768	05/16/2000	First	
	AO	US- 6,395,277	05/28/2002	Graham	
	AP	US- 6,265,379	07/24/2001	Donovan	
	AQ	US- 6,358,513	03/19/2002	Voet et al	
	AR	US- 6,328,977	12/11/2001	Donovan	
	AS	US- 6,306,423	10/23/2001	Donovan	
	AT	US- 6,312,708	11/06/2001	Donovan	

FOREIGN PATENT DOCUMENTS

Examiner Initials *	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ³ - Number ⁴ - Kind Code ⁵ (if known)				
	EE	WO02/089834	11/04/02	Imperial College Inovations		

Examiner
SignatureDate
Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet 3 of 10

Complete if Known

Application Number	10/732,703
Filing Date	December 10, 2003
First Named Inventor	Shengwin Li
Group Art Unit	Not Yet Assigned
Examiner Name	Not Yet Assigned
Attorney Docket Number	ALLE0002-100 (17665)

OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	AU	PARK and SIMPSON, "Inhalational poisoning by botulinum toxin and inhalation vaccination with its heavy-chain component," Infect. Immun. (2003) 71:1147-1154.	
	AV	ATASSI and OSHIMA, "Structure, activity and immune (T and B cell) recognition of botulinum neurotoxins," Crit. Rev. Immunol. (1999) 19:219-260.	
	AW	MARCHESE RAGONA, et al., "Management of parotid sialoceles with botulinum toxin," The Laryngoscope (1999) 109:1344-1346.	
	AX	WIEGAND, et al., "125-I labelled botulinum A neurotoxin: pharmacokinetics in cats after intramuscular injection," Naunyn-Schmiedeberg's Arch. Pharmacol. (1976) 292:161-165.	
	AY	HABERMANN, "125-I labeled neurotoxin from Clostridium botulinum A: preparation, binding to synaptosomes and ascent to the spinal cord," Naunyn-Schmiedeberg's Arch. Pharmacol. (1974) 281:47-56.	
	AZ	MOYER, et al., "Botulinum Toxin Type B: Experimental and Clinical Experience," in Therapy with Botulinum Toxin, Jankovic, ed., 1994, pp 71-84.	
	BA	GONELLE-GISPERT, "SNAP-25a and -25b isoforms are both expressed in insulin secreting cells and can function in insulin secretion," Biochem. J. (1999) 339:159-165.	
	BB	International Conference on Botulinum Toxin: Basic Science and Clinical Therapeutics," Mov. Disord. (1995) 10:361-408.	
	BC	HABERMAN, et al., "Tetanus toxin and botulinum A and C neurotoxins inhibit noradrenaline release from cultured mouse brain," J. Neurochem. (1988) 51:522-527.	
	BD	SANCHEZ-PRIETO, et al., "Botulinum toxin A blocks glutamate exocytosis from guinea pig cerebral cortical synaptosomes," Eur. J. Biochem. (1987) 165:675-681.	
	BE	PEARCE, "Pharmacologic characterization of botulinum toxin for basic science and medicine," Toxicon (date) 35:1373-1412.	

Examiner
SignatureDate
Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet 4 of 10

Complete if Known

Application Number	10/732,703
Filing Date	December 10, 2003
First Named Inventor	Shengwin Li
Group Art Unit	Not Yet Assigned
Examiner Name	Not Yet Assigned
Attorney Docket Number	ALLE0002-100 (17665)

OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	BF	BIGALKE, et al., "Botulinum A neurotoxin inhibits non-cholinergic synaptic transmission in mouse spinal cord neurons in culture," Brain Res. (1985) 360:318-324.	
	BG	HABERMANN, "Inhibition by tetanus and botulinum A toxin of the release of [3H] noradrenaline and [3H] GABA from rat brain homogenate," Experientia (1988) 44:224-226.	
	BH	BIGALKE, et al., "Tetanus toxin and botulinum A toxin inhibit release and uptake of various transmitters as studied with particulate preparations from rat brain and spinal cord," Naunyn-Schmiedelberg's Arch. Pharmacol. (1981) 316:244-251.	
	BI	JANCOVIC, et al., eds., "Therapy with Botulinum Toxin," New York, Marcel Dekkar, 1994. p.5.	
	BJ	SCHANTZ, et al., "Properties and use of botulinum toxin and other microbial neurotoxins in medicine," Microbial Rev. (1992) 56:80-99.	
	BK	SLOOP, et al., "Reconstituted botulinum toxin type A does not lose potency in humans if it is refrozen or refrigerated for two weeks before use," Neurology (1997) 48:249-253.	
	BL	GALBIATI, et al., "Identification, sequence and developmental expression of invertebrate flotillins from Drosophila melanogaster," Gene (1998) 210:229-237.	
	BM	LI, et al., "Src tyrosine kinases, Galpha subunits, and H-ras share a common membrane-anchored scaffolding protein, caveolin," J. Biol. Chem. (1996) 271:29182-29190.	
	BN	ISHIZAKA, et al., "Angiotensin II tyhpe receptor: Relationship with caveolae and caveolin after initial agonist simulation," Hypertension (1998) 32:459-466.	
	BO	JU, et al., "Inhibitory interactions of the bradykinin B2 receptor with endothelial nitric-acid synthase," J. Biol. Chem. (1998) 273:24025-24029.	
	BP	WEBB, et al., "SR-BII, an isoform of the scavenger receptor BI containing an alternate cytoplasmic tail, mediates lipid transfer between high density lipoprotein and cells," J. Biol. Chem. (1998) 273:15241-15248.	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet 5 of 10

Complete if Known

Application Number	10/732,703
Filing Date	December 10, 2003
First Named Inventor	Shengwin Li
Group Art Unit	Not Yet Assigned
Examiner Name	Not Yet Assigned
Attorney Docket Number	ALLE0002-100 (17665)

OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	BQ	DRAB, et al., "Loss of caveolae, vascular dysfunction, and primary defects in caveolin-1 gene-disrupted mice," Science (2001) 293:2449-2452.	
	BR	BOUILLOT, et al., "Axonal amyloid precursor protein expressed by neurons in vitro is present in a membrane fraction with caveolae-like properties," J. Biol. Chem. (1996) 271:7640-7644.	
	BS	RAZANI, et al., "Caveolae: From cell biology to animal physiology," Pharmacol. Rev. (2002) 54:431-467.	
	BT	LI, et al., "Phosphorylation of caveolin by src tyrosine kinases," J. Biol. Chem. (1996) 271:3863-3868.	
	BU	RAZANI and LISANTI, "Caveolin-deficient mice: insights into caveolar function and human disease," J. Clin. Invest. (2001) 108:1553-1561.	
	BV	GARCIA-CARDENA, et al., "Dissecting the interaction between nitric oxide synthase (NOS) and caveolin," J. Biol. Chem. (1997) 272:25437-25440.	
	BW	SOTGIA, et al., "Intracellular retention of glycoposphatidylinositol-linked proteins in caveolin-deficient cells," Mol. Cell. Biol. (2002) 22:3905-3926.	
	BX	FRANK, et al., "Influence of caveolin-1 on cellular cholesterol efflux mediated by high-density lipoproteins," Am. J. Physiol. Cell Physiol. (2001) 280:C1204-C1214.	
	BY	GALBIATI, et al., "Caveolin-1 expression negatively regulates cell cycle progression by inducing G0/G1 arrest via a p53/p21WAF1/Cip1-dependent mechanism," Mol. Biol. Cell. (2001) 12:2229-2244.	
	BZ	FRANK, et al., "Adenovirus-mediated expression of cavolin-1 in mouse liver increases plasma high-density lipoprotein levels," Biochemistry (2001) 40:10892-10900.	
	CA	LEE, et al., "Src-induced phosphorylation of caveolin-2 on tyrosine 19," J. Biol. Chem. (2002) 277:34556-34567.	

Examiner
SignatureDate
Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet

6

of

10

Complete if Known

Application Number	10/732,703
Filing Date	December 10, 2003
First Named Inventor	Shengwin Li
Group Art Unit	Not Yet Assigned
Examiner Name	Not Yet Assigned
Attorney Docket Number	ALLE0002-100 (17665)

OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	CB	COUET, et al., "Identification of peptide and protein ligands for the caveolin-scaffolding domain," J. Biol. Chem. (1997) 272:6525-6533.	
	CC	LEE, et al., "Constitutive and growth factor-regulated phosphorylation of caveolin-1 occurs at the same site (Tyr-14) in vivo: identification of a c-src/cav-1/grb7 signalling cassette," Mol. Endocrinol. (2000) 14:1750-1775.	
	CD	SATO, et al., "Reconstitution of src-dependent phospholipase C gamma phosphorylation and transient calcium release by using membrane rafts and cell-free extracts from Xenopus eggs," J. Biol. Chem. (2003) 278:38413-38420.	
	CE	GARGALOVIC and DORY, "Cellular apoptosis is associated with increased caveolin-1 expression in macrophages," J. Lipid Res. (2003) 44:1622-1632	
	CF	HAMER, et al., "Rational design of drugs that induce human immunodeficiency virus replication," J. Virol. (2003) 77:10227-10236.	
	CG	McINTOSH, et al., "Targeting endothelium and its dynamic caveolae for tissue-specific transcytosis in vivo: a pathway to overcome cell barriers to drug and gene delivery," Proc. Natl. Acad. Sci. USA (2002) 99:1996-2001	
	CH	LI, et al., "Baculovirus-based expression of mammalian caveolin in Sf21 insect cells," J. Biol. Chem. (1996) 271:28647-28654.	
	CI	LI, et al., "Expression and characterization of recombinant caveolin," J. Biol. Chem. (1996) 271:568-573.	
	CJ	DOBROSOTSKAYA, et al., "Reconstitution of sterol-regulated endoplasmic reticulum-to-Golgi transport of SREBP-2 in insect cells by co-expression of mammalian SCAP and insigs," J. Biol. Chem. (2003) 278:35837-35843.	
	CK	SCHNITZER, et al., "Endothelial caveolae have the molecular transport machinery for vesicle budding, docking, and fusion including VAMP, NSF, SNAP, annexins and GTPases," J. Biol. Chem. (1995) 270:14399-14404.	
	CL	HAYASHI, et al., "Amyloid precursor protein in unique cholesterol-rich microdomains different from caveolae-like domains," Biochim. Biophys. Acta (2000) 1483:81-90.	

Examiner
SignatureDate
Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet 7 of 10

Complete if Known

Application Number	10/732,703
Filing Date	December 10, 2003
First Named Inventor	Shengwin Li
Group Art Unit	Not Yet Assigned
Examiner Name	Not Yet Assigned
Attorney Docket Number	ALLE0002-100 (17665)

OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	CM	BANWAIT, et al., "Role of nitric acid in beta(3)-adrenoreceptor activation on basal tone of internal anal sphincter," Am. J. Physiol.-Gastroint. Liver Physiol. (2003) 285:G547-G555.	
	CN	McLOON and CHRISTIANSEN, "Increasing extraocular muscle strength with insulin-like growth factor," Invest. Ophthalmol. Visual Sci. (2003) 44:3866-3872.	
	CO	CARVER and SCHNITZER, "Caveolae: mining little caves for new cancer targets," Nature Reviews Cancer (2003) 3:571-581.	
	CP	SCHNITZER, "Caveolae: from basic trafficking mechanisms to targeting transcytosis for tissue-specific drug and gene delivery in vivo," Adv. Drug. Deliv. Rev. (2001) 28:265-280.	
	CQ	McINTOSH and SCHNITZER, "Caveolae require intact VAMP for targeted transport in vascular endothelium," Am. J. Physiol. (1999) 277:H2222-H2232.	
	CR	LEE, et al., "Tumor cell growth inhibition by caveolin re-expression in human breast cancer cells," Oncogene (1998) 16:1391-1397.	
	CS	PAJVANI, et al., "Structure-function studies of the adipocyte-secreted hormone Acrp30/adiponectin. Implications for metabolic regulation and bioactivity," J. Biol. Chem. (2003) 278:9073-9085.	
	CT	MYNARCIK, et al. "Adiponectin and leptin levels in HIV-infected subjects with insulin resistance and body fat redistribution," J. Acquir. Immun. Defic. Syndr. (2002) 31:514-520.	
	CU	RAJALA, et al., "Adipose-derived resistin and gut-derived resistin-like molecule-beta selectively impair insulin action on glucose production," J. Clin. Invest. (2003) 11:225-230.	
	CV	MENZAGHI, et al., "A haplotype at the adiponectin locus is associated with obesity and other features of the insulin resistance syndrome," Diabetes (2002) 51:2306-2312.	
	CW	IYENGAR, et al., "Adipocyte-sereted factors synergistically promote mammary tumorigenesis through induction of anti-apoptotic transcriptional programs and proto-oncogene stabilization," Oncogene (2003) 22:6408-6423.	

Examiner
SignatureDate
Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet 8 of 10

Complete if Known

Application Number	10/732,703
Filing Date	December 10, 2003
First Named Inventor	Shengwin Li
Group Art Unit	Not Yet Assigned
Examiner Name	Not Yet Assigned
Attorney Docket Number	ALLE0002-100 (17665)

OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	CX	COHEN, et al., "Role of caveolin and caveolae in insulin signaling and diabetes," Am. J. Physiol. Endocrinol. Metab. (2003) 285:E1151-E1160.	
	CY	KRATCHMAROVA, et al., "A proteomic approach for identification of secreted proteins during the differentiation of 3T3-L1 preadipocytes to adipocytes," Mol. Cell. Proteomics (2002) 1:213-222.	
	CZ	COMBS, et al., "Induction of adipocyte complement-related protein of 30 kilodaltons by PPARGamma agonists: a potential mechanism of insulin sensitization," Endocrinology (2002) 143:998-1007.	
	DA	BERG, et al., "ACRP30/adiponectin: an adipokine regulating glucose and lipid metabolism," Trends Endocrinol. Metab. (2002) 13:84-89.	
	DB	COMBS, et al., "Endogenous glucose production is inhibited by the adipose-derived protein Acrp30," J. Clin. Invest. (2001) 108:1875-1881.	
	DC	RAZANI, et al., "Caveolin-1-deficient mice are lean, resistant to diet-induced obesity, and show hypertriglyceridemia with adipocyte abnormalities," J. Biol. Chem. (2002) 277:8635-8647.	
	DD	SHIN, et al., "Involvement of cellular caveolae in bacterial entry into mast cells," Science (2000) 289:785-788.	
	DE	BURGUENO, et al., "Metabotropic glutamate type 1alpha receptor localizes in low-density caveolin-rich plasma membrane fractions," J. Neurochem. (2003) 86:785-791.	
	DF	TANG, et al., "Expression of metabotropic glutamate receptor 1alpha in the hippocampus of rat pilocarpine model of status epilepticus," Epilepsy Res. (2001) 46:179-189.	
	DG	CIRUELA, et al., "Metabotropic glutamate 1alpha and adenosine A1 receptors assemble into functionally interacting complexes," J. Biol. Chem. (2001) 276:18345-18351.	
	DH	ZHANG, et al., "Localization and regulation of the delta-opioid receptor in dorsal root ganglia and spinal cord of the rat and monkey: evidence for association with the membrane of large dense-core vesicles," Neuroscience (1998) 82:1225-1242.	

Examiner
SignatureDate
Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet 9 of 10

Complete if Known

Application Number	10/732,703
Filing Date	December 10, 2003
First Named Inventor	Shengwin Li
Group Art Unit	Not Yet Assigned
Examiner Name	Not Yet Assigned
Attorney Docket Number	ALLE0002-100 (17665)

OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	DI	SKOFF, et al., "Nerve growth factor (NF) and glial cell line-derived neurotrophic factor (GDNF) regulate substance P release in adult spinal sensory neurons," Neurochem. Res. (2003) 28:847-854.	
	DJ	SCHAIBLE, et al., "Mechanisms of pain in arthritis," Ann. NY Acad. Sci. (2002) 966:343-354.	
	DK	XU, et al., "On the role of galanin, substance P and other neuropeptides in primary sensory neurons of the rat: studies on spinal reflex excitability and peripheral axotomy," Eur. J. Neurosci. (1990) 2:733-743.	
	DL	TREVISANI, et al., "Ethanol elicits and potentiates nociceptor responses via the vanilloid receptor," Nat. Neurosci. (2002) 5:546-551.	
	DM	MALCANGIO, et al., "A novel control mechanism based on GDNF modulation of somatostatin release from sensory neurones," FASEB J. (2002) 16:730-732.	
	DN	SOUTHALL, et al., "Twenty-four hour exposure to prostaglandin down regulates prostanoid receptor binding but does not alter PGE(2)-mediated sensitization or rat sensory neurons," Pain (2002) 96:285-296.	
	DO	MARVIZON, et al., "Neurokinin 1 receptor internalization in spinal cord slices induce by dorsal root stimulation is mediated by NMDA receptors," J. Neurosci. (1997) 17:8129-8136.	
	DP	MORIOKA, et al., "Interleukin-1beta-induced substance P release from rat cultured primary afferent neurons driven by two phospholipase A2 enzymes: secretory type IIA and cystolic type IV," J. Neurochem. (2002) 80:989-997.	
	DQ	ALLEN, et al., "Noxious cutaneous thermal stimuli induce a graded release of endogenous substance P in the spinal cord: imaging peptide action in vivo," J. Neurosci. (1997) 17:5921-5927.	
	DR	HARRIS, et al., "Expression of caveolin by bovine lymphocytes and antigen-presenting cells," Immunology (2002) 105:190-195.	
	DS	SHIN and ABRAHAM, "Glycosylphosphatidylinositol-anchored receptor-mediated bacterial endocytosis," FEMS Microbiol. Lett. (2001) 197:131-138.	

Examiner
SignatureDate
Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet 10 of 10

Complete if Known

Application Number	10/732,703
Filing Date	December 10, 2003
First Named Inventor	Shengwin Li
Group Art Unit	Not Yet Assigned
Examiner Name	Not Yet Assigned
Attorney Docket Number	ALLE0002-100 (17665)

OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	DT	FIELD, et al., "Fc epsilon RI-mediated recruitment of p53/56lyn to detergent resistant membrane domains accompanies cellular signalling," Proc. Natl. Acad. Sci. USA (1995) 92:9201-9205.	
	DU	BAIG, et al., "Agonist activated adrenocorticotropin receptor internalizes via a clathrin-mediated G protein receptor kinase dependent mechanism," Endocrin. Res. (2002) 28:281-289.	
	DV	KOHNO, et al., "N-glycans of sphingosine 1-phosphate receptor Edg-1 regulate ligand-induced receptor internalization," FASEB J. (2002) 16:983-992.	
	DW	DALE, et al., "Agonist-stimulated and tonic internalization of metabotropic glutamate receptor 1a in human embryonic kidney 293 cells: agonist-stimulated endocytosis is beta-arrestin 1 isoform-specific," Mol. Pharmacol. (2001) 60:1243-1253.	
	DX	OSTROM, et al., "Receptor number and caveolar co-localization determine receptor coupling efficiency to adenylyl cyclase," J. Biol. Chem. (2001) 276:42063-42069.	
	DY	OSTROM, et al., "Stoichiometry and compartmentation in G protein-coupled receptor signalling: implications for therapeutic interventions involving G(s)," J. Pharmacol. Exp. Ther. (2000) 294:407-412.	
	DZ	RIDDELL, et al., "Compartmentalization of beta-secretase (Asp20) into low-bouyant density, noncaveolar lipid rafts," Curr. Biol. (2001) 11:1288-1293.	
	EA	ROUVINSKI, et al., "Both raft- and non-raft proteins associate with CHAPS-insoluble complexes: some APP in large complexes," Biochem. Biophys. Res. Comm. (2003) 308:750-758.	
	EB	IKEZU, et al., "Caveolae, plasma membrane microdomains for alpha-secretase-mediated processing of the amyloid secretory protein," J. Biol. Chem. (1998) 273:10485-10495.	

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.